News • Future lifesavers
Tiny robots are next step to precisely targeted drug delivery
A Stanford mechanical engineer creates multifunctional wireless robots to maximize health outcomes and minimize invasiveness of procedures.
A Stanford mechanical engineer creates multifunctional wireless robots to maximize health outcomes and minimize invasiveness of procedures.
Reseachers have developed a novel microneedle for injecting therapeutics into the eyes, potentially solving one of the major challenges of treating eye diseases.
Scientists at the La Jolla Institute for Immunology discover new drug target for severe asthma and fibrosis.
Researchers have developed advanced computer models, or “digital twins”, of diseases, with the goal of improving diagnosis and treatment.
Finding the right antibiotic dose is akin to a Goldilocks problem: give too little, and the infection will persist; too much, and side-effects will override the benefits of the therapy. To get it “just right”, Prof Dr Birgit Koch talks about dosing optimisation in the clinical setting.
A new study enables developers to determine vaccine safety via smart sensors that measure objective physiological parameters. This could end the reliance on subjective reports of study participants.
Bioengineers have shown they can eradicate advanced-stage ovarian and colorectal cancer in mice in as little as six days with a treatment that could be ready for human clinical trials later this year.
A new method involving deuterium can be used to stabilise compounds against degradation. This discovery could result in new drugs that can be taken in lower doses or less frequently.
Safety trials are underway for a Cambridge-led vaccine that could be used as a booster targeting Covid-19 virus variants and relatives that threaten future coronavirus pandemics.
The light from a smartphone screen can be used to print medications, in a new 3D printing technique developed by UCL researchers.
Treating diseases such as Alzheimer’s or Parkinson’s is a challenge because drugs have to be able to cross the blood–brain barrier. As a result, the doses administered must be high and only a small fraction reaches the brain, which can lead to significant systemic side effects.
Classic antidepressants could help improve modern cancer treatments. They slowed the growth of pancreatic and colon cancers in mice, and when combined with immunotherapy, they even stopped the cancer growth long-term. In some cases the tumors disappeared completely, researchers at the University of Zurich (UZH) and University Hospital Zurich (USZ) have found. Their findings will now be tested in…
A treatment combining two antibodies is recommended for two specific groups of patients with Covid-19 by a WHO Guideline Development Group panel of international experts and patients.
The FDA approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions.
Common medications can accumulate in gut bacteria, a new study has found, altering bacterial function and potentially reducing the medications’ effectiveness. These interactions - seen for many drugs including those used to treat depression, diabetes, and asthma - could help researchers to better understand how drug effectiveness and side-effects differ between individuals. The study is…
Researchers in Thailand have developed a device to get the most out of vaccine supplies: The automated vaccine filling machine from the Faculty of Engineering at Chulalongkorn University can fill AstraZeneca vaccine into syringes with precision, speed, and safety, helping to increase the number of vaccinated people by 20 percent. The prototype is now operating at Chula Vaccination Center and more…
Adults who have received a double vaccination are 49% less likely to have Long Covid should they contract a Covid-19 infection, according to new research from King's College London. The scientists analysed data from participants logging their symptoms, tests and vaccines on the UK ZOE COVID Symptom Study app between 8th December 2020 and 4 July 2021, including 1,240,009 (first dose) and 971,504…
The first large-scale, long-term trial of a new strategy using combinations of very low-doses in one capsule, has demonstrated significantly improved control of high blood pressure - the leading cause of heart attack and stroke. This first large-scale, randomised controlled clinical trial of starting this novel combination blood pressure medication brought blood pressure under control in 80…
A nationwide US study has shown that the rate of opioid-related cardiac arrests has steeply risen and is now on par with the rate of cardiac arrest from other causes. The research is presented at ESC Congress 2021. Opioid use disorder, which includes dependence and addiction, affects more than two million people in the US, while opioid overdose is the leading cause of death for those aged 25 to…
A novel study published in AACC’s The Journal of Applied Laboratory Medicine shows that delaying the second Covid-19 vaccine dose for more than the recommended 3-4 weeks results in higher antibody levels. This finding could play a vital role in shaping vaccine distribution strategies that increase access to the vaccine around the globe.
Roche announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen (previously IONIS-HTTRx and RG6042) in manifest Huntington’s disease (HD). The decision was based on the results of a pre-planned review of the data from the Phase III study conducted by an unblinded Independent Data Monitoring Committee (iDMC). The iDMC made its recommendation based on the…
David Johnson, Global Director Commercial Excellence at ADVANZ PHARMA, explains the value of off-patent medicines to hospitals and healthcare systems, as the repercussions of the Covid-19 pandemic are still having a significant impact on resources.
To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions for TB patients worldwide, a new consortium of 30 partners from 13 countries has officially launched. The 7-year, €185 million project called Unite4TB, aims to accelerate and improve the clinical evaluation of combinations of existing and novel drugs, with the goal of developing…
Dr. Hayder Amin and Dr. Caghan Kizil from the DZNE’s Dresden site aim to speed up developing drugs against brain diseases through cutting-edge technology. To this end, they are generating an innovative technology platform, termed “i3D-Markers”, based on high-density microelectrode arrays and 3-dimensional networks of human neurons. Compounds to be tested will be dripped onto this setup, and…
Statin use among patients with heart failure is associated with a 16% lower risk of developing cancer compared with non-statin users during an average of four years of follow-up. This is according to new research published in the European Heart Journal. In addition, the study found that statin use was associated with a 26% reduced risk of dying from cancer over the same period.